Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial

详细信息    查看全文

• 作者：Rury R. Holman ; FRCP^a ; ^{rury.holman@dtu.ox.ac.uk" class="auth_mail} ; Mary A. Bethel ; MD^a ; Juliana C.N. Chan ; MD^b ; Jean-Louis Chiasson ; MD^c ; Zoë ; Doran ; RN^a ; Junbo Ge ; MD^d ; Hertzel Gerstein ; MD ; MSc^e ; Yong Huo ; MD^f ; John J. McMurray ; MD^g ; Lars Ryden ; MD ; PhD^h ; Winitha Liyanage ; MSc^a ; Stefan Schrö ; der ; PhDⁱ ; Michal Tendera ; MD^j ; Michael J. Theodorakis ; MD PhD^a ; Jaakko Tuomilehto ; MD ; MA ; PhD^k ; Wenying Yang ; MD^l ; Dayi Hu ; MD^m ; Changyu Pan ; MDⁿ ; for the ACE Study Group
• 刊名：American Heart Journal
• 出版年：July 2014
• 年：2014
• 卷：168
• 期：1
• 页码：23-29.e2
• 全文大小：368 K

文摘

Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an 伪-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.